Literature DB >> 31558231

Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.

Wenfeng Fang1, Yihua Huang1, Jiadi Gan1, Yang W Shao2, Li Zhang3.   

Abstract

Entities:  

Year:  2019        PMID： 31558231     DOI： 10.1016/j.jtho.2019.05.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

Authors:  René J Boosman; Jacobus A Burgers; Egbert F Smit; Neeltje Steeghs; Anthonie J van der Wekken; Jos H Beijnen; Alwin D R Huitema; Rob Ter Heine
Journal:  Drugs       Date:  2021-12-11       Impact factor: 9.546

2.  Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations.

Authors:  Ling Lin; Xiaomai Wu; Shuangquan Yan; Yefei Zhu; Zhengqing Yan; Dongqing Lv; Hongfei Ge
Journal:  Onco Targets Ther       Date:  2020-09-30       Impact factor: 4.147

Review 3.  EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.

Authors:  Alex Friedlaender; Vivek Subbiah; Alessandro Russo; Giuseppe Luigi Banna; Umberto Malapelle; Christian Rolfo; Alfredo Addeo
Journal:  Nat Rev Clin Oncol       Date:  2021-09-24       Impact factor: 66.675

Review 4.  Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).

Authors:  Jingyi He; Zhengrong Huang; Linzhi Han; Yan Gong; Conghua Xie
Journal:  Int J Oncol       Date:  2021-09-24       Impact factor: 5.650

Review 5.  Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.

Authors:  Andreas Koulouris; Christos Tsagkaris; Anna Chiara Corriero; Giulio Metro; Giannis Mountzios
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.